Hubei Guangji Pharmaceutical Co., Ltd. operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Guangji Pharmaceutical Co., Ltd. with three other
pharmaceutical manufacturers in Asia:
CKD Bio Corp
of South Korea
sales of 113.01 billion Korean Won [US$101.15 million]
Wai Yuen Tong Medicine Holdings Ltd
of Hong Kong
(825.33 million Hong Kong Dollars [US$106.28 million]
Hwail Pharmaceutical Company Limited
based in South Korea
(111.52 billion Korean Won [US$99.81 million]
Hubei Guangji Pharmaceutical Co., Ltd. reported sales of 709.98 million Chinese Renmimbi (US$103.15 million)
December of 2016.
increase of 26.9%
versus 2015, when the company's sales were 559.56 million Chinese Renmimbi.
Sales of Pharmaceutical Products saw an increase
27.8% in 2016, from
556.83 million Chinese Renmimbi to 711.44 million Chinese Renmimbi.
Not all segments of Hubei Guangji Pharmaceutical Co., Ltd. experienced an increase in sales in 2016:
sales of Other Business fell 6.9% to 3.28 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).